Financial Performance - The company's revenue for Q3 2023 was ¥138,627,619.85, representing a decrease of 12.30% compared to the same period last year[5] - Net profit attributable to shareholders was ¥23,348,120.24, down 37.86% year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥21,834,417.67, a decline of 41.34% compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.07, reflecting a decrease of 36.36% from the same quarter last year[6] - Total revenue for the first three quarters of 2023 was CNY 459,487,529.22, a decrease of 3.1% compared to CNY 476,221,538.79 in the same period of 2022[20] - Operating costs for the first three quarters of 2023 were CNY 393,013,923.73, slightly down from CNY 393,895,293.76 in 2022[20] - Net profit for Q3 2023 was CNY 113,504,894.78, an increase of 10.0% from CNY 102,486,877.63 in Q3 2022[21] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.35, up from CNY 0.31 in Q3 2022[23] Assets and Liabilities - Total assets increased to ¥1,833,980,462.20, marking a growth of 6.68% from the end of the previous year[6] - Total assets as of Q3 2023 amounted to CNY 1,833,980,462.20, compared to CNY 1,719,093,524.95 in Q3 2022, reflecting a growth of 6.7%[19] - Total liabilities increased to CNY 685,911,170.65 in Q3 2023 from CNY 628,161,634.93 in Q3 2022, marking a rise of 9.2%[19] - Shareholders' equity reached CNY 1,148,069,291.55 in Q3 2023, compared to CNY 1,090,931,890.02 in Q3 2022, indicating an increase of 5.2%[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥124,610,776.23, an increase of 16.75%[5] - In the first three quarters of 2023, the net cash flow from operating activities was ¥124,610,776.23, an increase of 16.5% compared to ¥106,729,566.50 in the same period of 2022[24] - Total cash inflow from operating activities was ¥492,891,005.54, while cash outflow was ¥368,280,229.31, resulting in a net cash inflow of ¥124,610,776.23[24] - Cash flow from investing activities showed a net outflow of ¥45,109,147.48, a significant improvement from a net outflow of ¥187,319,159.87 in the previous year[25] - Cash inflow from financing activities was ¥250,319,618.00, while cash outflow was ¥234,883,799.29, leading to a net cash inflow of ¥15,435,818.71[25] - The company reported a cash and cash equivalents balance of ¥308,365,117.60 at the end of the third quarter, up from ¥195,984,125.00 at the end of the same period last year[25] Investments and Expenses - The company reported a significant increase in short-term borrowings by 148.55%, primarily due to increased bank loans[10] - The company's investment income for the year-to-date rose by 42.06%, indicating improved returns from external investment projects[10] - Research and development expenses for Q3 2023 were CNY 35,398,105.34, slightly up from CNY 35,003,808.66 in Q3 2022[21] - The company reported a financial expense of CNY 5,219,582.71 in Q3 2023, significantly higher than CNY 1,585,591.42 in Q3 2022[21] - The company invested ¥56,362,447.48 in fixed assets and intangible assets during the third quarter, a decrease from ¥198,789,078.37 in the same quarter of the previous year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,800[13] - The largest shareholder, Yan Yiyi, holds 23.58% of the shares, totaling 77,192,080 shares[14] Other Financial Metrics - The weighted average return on equity decreased to 2.12%, down 1.59 percentage points from the previous year[6] - The company experienced a 54.34% increase in minority interests, mainly due to capital injections from minority shareholders in a subsidiary[10] - The company received ¥14,029,107.02 in tax refunds, a significant increase from ¥648,018.86 in the previous year[24] - The company raised ¥2,100,000.00 from minority shareholders as part of its financing activities[25] - The company’s cash flow from operating activities was positively impacted by a reduction in tax payments, which decreased from ¥49,335,000.04 to ¥35,920,189.47[24] - The company experienced a foreign exchange gain of ¥17,046.68 during the third quarter[25]

一、报告期内，公司主营业务分行业、分产品经营情况： 单位：元 币种：人民币 | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率（%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比上 | | | | | | | | 年增减（%） | | | | | | 减（%） | 减（%） | | | 医药制造业 | 458,786,261.23 | 165,699,261.87 | 63.88 | -2.65 | 10.77 | -4.38 | | | | 主营业务分产品情况 | | | | | | 分产品 | 营业收入 | 营业成本 | 毛利率（%） | 营业收入 比上年增 | 营业成本 | 毛利率比上 年增减（%） | | | | | | | 比上年增 | | | | | | | 减（%） | 减（%） | | | 制剂 | 354,102,688.11 | 106,850,295.22 | 69.83 | -8.52 | 4.40 | -3.74 | | 原料药 ...

证券代码： 603811 证券简称：诚意药业 公告编号：2023-027 浙江诚意药业股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2023 年 9 月 8 日召开 2023 年第一次临时股东大会，审议通过了《关于修订<浙江诚意药业股份有限公 司章程>的议案》，本次修订涉及到经营范围的变更。具体内容详见公司于 2023 年 9 月 9 日在上海证券交易所网站及指定媒体披露的《2023 年第一次临时股东 大会决议》（公告编号：2023-025）。 公司已于近日完成了上述经营范围的变更登记，现已取得浙江省市场监督管 理局换发的《营业执照》。相关登记信息如下： 统一社会信用代码：913303007303249630 名称：浙江诚意药业股份有限公司 类型：股份有限公司（上市、自然人投资或控股） 住所：温州市洞头区化工路 118 号 法定代表人：赵春建 注册资本：人民币 32730.432 万元 成立日期：2001 年 06 ...

浙江诚意药业股份有限公司 关于控股子公司获得化学原料药上市 申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码： 603811 证券简称：诚意药业 公告编号：2023-026 二、 药品的其他相关情况 氨基葡萄糖是一种天然的氨基单糖，是蛋白多糖的前体物质，可以刺激软骨 细胞产生有正常多聚体结构的蛋白多糖，提高软骨细胞的修复能力，并防止损伤 细胞的超氧化自由基的产生，可以促进软骨基质的修复和重建，从而可延缓骨关 节疼痛的病理过程和疾病的进程，改善关节活动，缓解疼痛。盐酸氨基葡萄糖主 要用于治疗骨关节炎和膳食补充剂，安全性较高，其为人体及动物体内关节组织 中糖蛋白的天然成分，具有修复和维持软骨及关节功能的作用。 近日，浙江诚意药业股份有限公司（以下简称"公司"）控股子公司福建华 康药业有限公司（以下简称"福建华康"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于原料药盐酸氨基葡萄糖《化学原料药上市申请 批准通知书》，现将情况公告如下： 一、 化学原料药基本情况 化学原料药名称：盐 ...

证券代码：603811 证券简称：诚意药业 公告编号：2023-025 浙江诚意药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 11 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 100,842,247 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 30.8099 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，以现场和网络投票相结合的方式召开，现 场会议由公司董事长颜贻意先生主持。本次股东大会的召集、召开和表决方式符 (一) 股东大会召开的时间：2023 年 09 月 08 日 (二) 股东大会召开的地点：浙江省温州市洞头区化工路 118 号浙江诚意药业 股份有限公司洞头制造部研发大楼会议室 (三) 出席会议 ...

地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 上海市锦天城律师事务所 关于浙江诚意药业股份有限公司 2023 年第一次临时股东大会的 法律意见书 2023 年第一次临时股东大会的 法律意见书 致：浙江诚意药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江诚意药业股份有限 公司（以下简称"公司"）委托，就公司召开 2023 年第一次临时股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上市公司股东大会规则》等法律、法规、规章和其他规范性文件 以及《浙江诚意药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关 ...

股票简称：诚意药业 股票代码：603811 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议资料 2023 年 9 月 8 日 1/6 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议资料目录 ● 会议议案 | 序号 | 议案名称 | | --- | --- | | 1 | 关于修订公司章程的议案 | 2/6 ● 会议须知 ● 会议议程 浙江诚意药业股份有限公司 2023 年第一次临时股东大会 会议须知 为维护浙江诚意药业股份有限公司（以下简称"公司"）全体股东的合法权益，确 保股东大会的正常秩序和议事效率，保证大会的顺利进行，特制定本会议须知，请出席 股东大会的全体人员遵照执行： 一、参会资格：股权登记日 2023 年 9 月 4 日下午收盘后，在中国证券登记结算有 限责任公司上海分公司登记在册的持有本公司股票的股东。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务必请出席 现场大会的股东或股东代表携带相关证件，提前到达会场登记参会资格并签到。未能提 供有效证件办理签到的，不能参加现场表决和发言。除了股东授权代理人、公司董事、 监事、高级管理人员、公司聘请的见证 ...

证券代码：603811 证券简称：诚意药业 公告编号：2023-024 浙江诚意药业股份有限公司 关于2023年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日上午 09:00-10:00 在上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 通过网络文字互动方式召开 2023 年半年度业绩说明会。现将有关事项公告如下： 一、业绩说明会召开情况 2023 年 8 月 17 日，公司在上海证券交易所网站（www.sse.com.cn）及指定信 息媒体披露了《浙江诚意药业股份有限公司关于召开 2023 年半年度业绩说明会的 公告》（公告编号：2023-019）。 2023 年 8 月 25 日上午 09:00-10:00，公司总经理赵春建先生、副总经理任秉 钧先生、副总经理厉市生先生、董事会秘书柯泽慧女士、财务总监吕孙战先生、独 立董事陈志刚先生出席了本次业绩说明会。与投资者进行互 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥320.86 million, a slight increase of 0.85% compared to ¥318.16 million in the same period last year[20]. - Net profit attributable to shareholders of the listed company reached approximately ¥90.60 million, representing a significant increase of 39.48% from ¥64.96 million in the previous year[20]. - The net cash flow from operating activities increased by 50.63% to approximately ¥107.39 million, up from ¥71.29 million in the same period last year[20]. - Basic earnings per share rose to ¥0.28, a 40% increase compared to ¥0.20 in the same period last year[21]. - The weighted average return on net assets increased to 8.06%, up by 1.62 percentage points from 6.44% in the previous year[21]. - The total assets of the company at the end of the reporting period were approximately ¥1.79 billion, an increase of 4.19% from ¥1.72 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 2.95% to approximately ¥1.12 billion, compared to ¥1.09 billion at the end of the previous year[20]. - The increase in net profit was primarily due to a significant rise in investment income and a reduction in losses from the subsidiary Jiangsu Chengyi[22]. Market Position and Product Development - The company secured over 41% market share for its main product, Glucosamine Hydrochloride Capsules, in nine provinces[28]. - Four new health food products were launched, with plans for multi-channel promotion to drive sales growth[29]. - The company is actively participating in national pharmaceutical bidding, with significant success in securing contracts[28]. - The company has ten new products under research, including L-Carnitine Injection and Voriconazole API, which have been successfully accepted for filing[29]. - The company plans to enhance its product line through ongoing research and potential acquisitions in the oncology and liver protection sectors[30]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million allocated for potential deals[75]. Operational Efficiency and Management - The company plans to continue focusing on investment opportunities and improving operational efficiency to sustain growth in the future[22]. - The company has implemented comprehensive risk management strategies to ensure sustainable sales growth[28]. - The company’s marketing center in Shanghai aims to build a robust global sales network by recruiting top marketing talent[28]. - Ongoing research and development efforts have led to the introduction of two new technologies that are anticipated to enhance operational efficiency by 10%[76]. - The company is focusing on enhancing its technological capabilities to improve operational efficiency and product offerings[138]. Environmental Compliance and Sustainability - The company maintained compliance with environmental regulations, with no pollution incidents reported during the reporting period[51]. - The company has implemented a combination of clean production and end-of-pipe treatment to enhance environmental protection efforts[56]. - The company has taken measures to reduce carbon emissions, including solar rooftop photovoltaic power generation and smart energy digital management[70]. - The company has established an emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[67]. Shareholder and Capital Management - The company did not propose any profit distribution or capital reserve transfer plans for the half-year period[48]. - The company has a commitment to stabilize its stock price for three years following its IPO, with conditions based on stock performance over 20 consecutive trading days[83]. - If the stock price falls below the latest audited net asset value per share, the company and its major shareholders will initiate measures to stabilize the stock price[83]. - The company plans to repurchase shares to stabilize the stock price, subject to legal and regulatory compliance[84]. - Shareholders must approve any share repurchase decision with at least two-thirds of the voting rights at the meeting[84]. Financial Health and Investments - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[75]. - The total assets of the company at the end of the reporting period are 1,087,885,213.00, showing a growth from 986,308,389.00 in the previous year[142]. - The company has allocated 90,599,041.00 for capital reserves, which is a strategic move to strengthen its financial position[139]. - The overall equity of the company increased to 994,681,383 RMB, reflecting strong financial health and investor confidence[153]. Governance and Compliance - The company has established a structured governance framework, including a board of directors and various specialized committees[161]. - The financial statements comply with the disclosure requirements set forth by the China Securities Regulatory Commission[164]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position and operating results[167].

证券代码：603811 证券简称：诚意药业 公告编号：2023-019 浙江诚意药业股份有限公司 关于召开2023年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 会议召开时间：2023 年 08 月 25 日(星期五)上午 09:00-10:00 ● 会议召开网址：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络文字互动方式 ● 投资者可于 2023 年 08 月 18 日(星期五)至 08 月 24 日(星期四)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）将于 2023 年 08 月 24 日发布 公司 2023 年半年度报告，为便于广大投资者更全面深 ...